Combination Of Curcumin And Bicalutamide Enhanced The Growth Inhibition Of Androgen-independent Prostate Cancer Cells Through SAPK/JNK And MEK/ERK1/2 Mediated Targeting NF-κB/p65 And MIC1-C

ObjectiveProstate cancer is one of the most common malignancies in men. The mucin 1 (MUCl)heterodimeric oncoprotein is overexpressed in human prostate cancers with aggressivepathologic and clinical features, resulting in a poor outcome. However, the functional role for MUCl C-terminal domain (MUCl-C) in androgen-independent prostate cancer occurrenceand development has remained unclear.MethodsCell viability was measured by MTT assays. Western blot analysis was performed to measure the phosphorylation and protein expression of SAPK/JNK and ERK1/2, and MUC1-C, NF-κB subunit p65 and p50. Exogenous expression of MUC1-C, NF-κB subunit p65 was carriedout by transient and electroporated transfection assays.ResultsWe showed that curcumin inhibited the growth of androgen-independent prostate cancer cells and a synergy was observed in the presence of curcumin and bicalutamide, the androgen receptor antagonist. To further explore the potential mechanism underlining this, we found that curcumin increased the phosphorylation of ERK1/2 and SAPK/JNK, which was enhanced by bicalutamide. In addition, curcumin reduced the protein expression of MUCl-C and NF-κB subunit p65, which were abrogated in the presence of the inhibitors of MEK/ERK1/2 (PD98059) and SAPK/JNK (SP60015). A further reduction was observed in the combination of curcumin with bicalutamide. Moreover, while exogenous expression of MUCl-C had little effect on curcumin-reduced p65, the overexpression of p65 reversed the effect of curcumin on MUC1-C protein expression suggesting that p65 is upstream of MUC1-C. Intriguingly, we showed that exogenous expression of MUC1-C feedback diminished the effect of curcumin on phosphorylation of ERK1/2 and SAPK/JNK, and antagonized the effect of curcumin on cell growth. ConelusionOur results show that curcumin inhibits the growth of androgen-independent prostate cancer cells through ERK1/2-and SAPK/JNK-mediated inhibition of p65, followed by reducing expression of MUC1-C protein. More importantly, there are synergistic effects of curcumin and bicalutamide. The negative feedback regulatory loop of MUC1-C to ERK1/2 and SAPK/JNK further demonstrates the role of MUC1-C that contributes to the overall responses of curcumin. This study unveils the potential molecular mechanism by which combination of curcumin with bicalutamide enhances the growth inhibition of androgenindependent prostate cancer cells.